Pancreatic neuroendocrine tumors (pNETs) differ in their clinical behavior, presentation and
prognosis based on their initial histological features and disease stage. While small …

Abstract Background In China, there are currently no approved therapies for the treatment of
metastatic renal cell carcinoma (mRCC) following progression with vascular endothelial …

Drug-induced lung injury (DLI) comprises a wide variety of pathologies, each with a unique
imaging pattern, so there are no characteristic imaging findings to establish diagnosis. When …

Background Inhibition of the mammalian target of rapamycin (mTOR) is an established
treatment for multiple malignancies. We carried out an up-to-date meta-analysis to …

Multiple systemic therapies are available for the treatment of metastatic renal cell carcinoma
(mRCC), including mammalian target of rapamycin (mTOR), vascular endothelial growth …

Because of the potentially high mortality rate (6.5%) associated with bortezomib‐induced
lung disease (BILD) in J apanese patients with relapsed or refractory multiple myeloma, we …

In recent years, a number of new molecules–commonly known as biological therapies–have
been approved or are in late stages of regulatory evaluation for the treatment of advanced …

Background This study investigated the incidence, radiographic patterns, and relevance to
clinical outcome of everolimus‐related pneumonitis (ERP) in patients with metastatic breast …

Severe delayed drug hypersensitivity reactions comprise different clinical entities and can
involve different immune-mediated mechanisms. Common examples are severe cutaneous …

Background: A relevant percentage of patients with metastatic renal cell carcinoma develop
intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr …